Patents Assigned to Bristol-Myers Sqibb Company
  • Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
    Patent number: 6573262
    Abstract: The invention comprises substituted indoleoxoacetic piperazine derivatives of general Formula I, compositions thereof and their use as antiviral agents, and particularly for treating HIV infection.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: June 3, 2003
    Assignee: Bristol-Myers Sqibb Company
    Inventors: Owen B. Wallace, Tao Wang, Kap-Sun Yeung, Bradley C. Pearce, Nicholas A. Meanwell, Zhilei Qiu, Haiquan Fang, Qiufen May Xue, Zhiwei Yin
  • Methods for inhibiting the production of HIV-1 retrovirus using monoclonal antibodies and Fv specific for CD2 antigen
    Patent number: 6384198
    Abstract: An anti-CD2 monoclonal antibody according to the present invention can be: (1) a chimeric nonclonal antibody CD2 SFv-Ig produced by expression of the construct cloned in recombinant Escherichia coli culture ATCC No. 69277; (2) a monoclonal antibody having complementarity-determining regions identical with those of CD2 SFv-Ig; or (3) a monoclonal antibody competing with CD2 SFv-Ig for binding to CD2 antigen at least about 80% as effectively on a molar basis as CD2 SFv-Ig. Anti-CD2 monoclonal antibodies according to the present invention, as well as other antibodies that can modulate the interactions between T lymphocytes and monocytes, can be used to inhibit the production of HIV-1 by HIV-1-infected T cells in HIV-1-infected patients. In another use, T cells treated in vitro can be reinfused into AIDS patients to increase the proportion of functional non-HIV-1-producing T cells in the patient.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: May 7, 2002
    Assignee: Bristol-Myers Sqibb Company
    Inventors: Michael L Diegel, Peter S Linsley, Lisa K Gilliland, Patricia A Moran, Joyce M Zarling, Jeffrey A Ledbetter